Felpreva®, Vetoquinol’s New Three-Monthly Feline Parasiticide, Receives Marketing Authorisation from the European Commission
22 November 2021 - 10:32AM
Business Wire
- Felpreva ® (tigolaner/emodepside/praziquantel) has been granted
marketing authorisation by the European Commission
- The combination product is the first spot-on solution for cats
approved in the EU to treat both internal and external parasite
infestations/infections, including tapeworms, for up to three
months
- Tigolaner, one of the three active compounds in Felpreva®, is a
novel active substance targeting fleas, ticks and mites
Vetoquinol (Paris: VETO) is delighted to announce that,
following positive opinion from the Committee for Medicinal
Products for Veterinary Use (CVMP), the European Commission has
granted marketing authorisation for Felpreva®
(tigolaner/emodepside/praziquantel) for spot-on prevention and
treatment of mixed parasitic infestations/infections in cats.1
Felpreva® is the first spot-on parasiticide for cats that covers
tapeworms in addition to other endoparasites including
gastrointestinal roundworms and lungworms, and ectoparasites
(fleas, ticks and mites) for up to three months with a single dose.
It is licensed for treatment of cats with, or at risk from, mixed
parasitic infestations/infections, including:
- Endoparasites: - Gastrointestinal roundworms: infection
with Toxocara cati, Toxascaris leonina and Ancylostoma tubaeforme -
Lungworms: infection with Aelurostrongylus abstrusus and
Troglostrongylus brevior - Tapeworms: infection with Dipylidium
caninum and Taenia taeniaeformis - Ectoparasites: - Flea
(Ctenocephalides felis), tick (Ixodes ricinus, Ixodes holocyclus)
and mite (Otodectes cynotis) infestations, as well as mild to
moderate cases of notoedric mange (caused by Notoedres cati). It
can also form part of a treatment strategy for flea allergic
dermatitis (FAD).
Matthieu Frechin, Vetoquinol CEO, commented: “Marketing
authorisation is a pivotal achievement for both Vetoquinol and
Felpreva®. It is a breakthrough treatment with convenience and
simplicity of use combined with long-lasting efficacy. We believe
that Felpreva® will be a real game changer for this area of
veterinary medicine, demonstrating our commitment to the
parasiticide market.”
Felpreva® is part of the endectocide class of veterinary
parasiticides that covers both internal (endo) and external (ecto)
parasites. It is a combination of active substances emodepside and
praziquantel, with tigolaner, a novel active ingredient.1
It is estimated that parasiticides make up the largest segment
in the companion animal veterinary pharmaceutical market worldwide.
Moreover, the fast-growing endectocide category is estimated to
make up approximately one quarter of the total companion animal
parasiticide market.2
Fifty percent of pet owners in Europe report currently treating
their pets with an endectocide product.3 However, research suggests
owners are treating cats less frequently than recommended by the
European Scientific Counsel Companion Animal Parasites (ESCCAP),
which recommends no less than four times per year for deworming in
certain risk groups of cats.4.5
Juliana Carrer, International Range Manager at Vetoquinol, said:
“With veterinary staff busier than ever, and increasing numbers of
new cat owners across Europe, we understand the need to reduce
prescribing complexity and increase vets’ confidence in owner
compliance. As a qualified veterinarian myself I warmly welcome the
approval of Felpreva®.”
It is anticipated that Felpreva® will be made available to
veterinarians across Europe in early 2022.
ENDS
References
- European Commission Union Register of Veterinary Medicinal
Products – Felpreva. 2021. Available from: https://ec.europa.eu/health/documents/community-register/html/v277.htm
[Accessed 16 November 2021].
- Vetoquinol estimates, based on Market Intelligence Data.
- Survey of Pet Owners in EU6 countries and the UK, conducted by
Metyis February 2021.
- McNamara, J., Drake, J., Wiseman, S. and Wright, I., 2018.
Survey of European pet owners quantifying endoparasitic infection
risk and implications for deworming recommendations. Parasites
& Vectors, 11(1).
- ESCCAP Guideline 1: Worm Control in Dogs and Cats. 6th ed.
Available at: https://www.esccap.org/uploads/docs/oc1bt50t_0778_ESCCAP_GL1_v15_1p.pdf
[Accessed 16 November 2021].
ABOUT VETOQUINOL Vetoquinol is a leading global animal health
company that supplies drugs and non-medicinal products for the
livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and
sells veterinary drugs and non-medicinal products in Europe, the
Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy
combining innovation with geographical diversification. The Group’s
hybrid growth is driven by the reinforcement of its product
portfolio coupled with acquisitions in high potential growth
markets. Vetoquinol employed 2,540 people as of September 30th,
2021.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME
personal equity plans.
For further information, go to: www.vetoquinol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122006075/en/
For more information, contact:
MIND+MATTER (Vetoquinol’s PR Partner agency) Theresa
Baker: Email: theresa.baker@ashfieldhealth.com
VETOQUINOL International Range Manager – Companion Animal
Parasiticides Juliana Carrer: Email: juliana.carrer@vetoquinol.com
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024